15 Results

People

  1. Ulaner
    Ulaner
  2. Chandarlapaty
    Chandarlapaty
  3. Baselga
    Baselga
  4. Hudis
    Hudis
  5. Hyman
    Hyman
  6. Jhaveri
    Jhaveri
  7. Lewis
    Lewis
  8. Modi
    Modi
  9. Riedl
    Riedl
  10. Berger
    Berger

Groups

  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (15)
  2. Breast Medicine Service (15)
  3. Department of Medicine (15)
  4. GSK Faculty (15)
  5. Human Oncology and Pathogenesis Program (15)
  6. Molecular Imaging and Therapy Service (15)
  7. Radiology, Department of (15)
  8. Solid Tumor Oncology Division (15)
  9. Epidemiology and Biostatistics (6)
  10. Biostatistics Service (5)
  1. "Molecular Imaging and Therapy Service"
  2. "Breast Medicine Service"
  3. "Sarat Chandarlapaty"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (6)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (15)
  2. Breast Medicine Service (15)
  3. Department of Medicine (15)
  4. GSK Faculty (15)
  5. Human Oncology and Pathogenesis Program (15)
  6. Molecular Imaging and Therapy Service (15)

More Groups

People
  1. Sarat Chandarlapaty (15)
  2. Gary Ulaner (12)
  3. Christopher Riedl (3)
  4. Clifford Hudis (3)
  5. David Hyman (3)
  6. Jason Lewis (3)

More People

Years
  1. 2023 (1)
  2. 2021 (2)
  3. 2020 (5)
  4. 2019 (3)
  5. 2018 (1)
  6. 2016 (1)

More Years

Publications
  1. Journal of Clinical Oncology (5)
  2. Cancer Research (4)
  3. Journal of Nuclear Medicine (2)
  4. Cancer Discovery (1)
  5. Journal of Vascular and Interventional Radiology (1)
  6. Radiology (1)

More Publications

Publishers
  1. American Association for Cancer Research (5)
  2. American Society of Clinical Oncology (5)
  3. Society of Nuclear Medicine (2)
  4. Elsevier Science, Inc. (1)
  5. Oxford University Press (1)
  6. Radiological Society of North America, Inc. (1)

Results (15)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers
    Meeting Abstract

    Liu, D.; Makker, V.; Buonocore, D. J.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Johnson, A.; Offin, M.; Solit, D. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1/2 study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), as monotherapy and in combination with other anti-cancer therapies in postmenopausal women with ER-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC): AMEERA-1
    Meeting Abstract

    Linden, H. M.; Campone, M.; Bardia, A.; Ulaner, G. A.; Gosselin, A.; Doroumian, S.; Pelekanou, V.; Celanovic, M.; Chandarlapaty, S.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Head-to-head evaluation of (18)F-FES and (18)F-FDG PET/CT in metastatic invasive lobular breast cancer
    Journal Article

    Ulaner, G. A.; Jhaveri, K.; Chandarlapaty, S.; Hatzoglou, V.; Riedl, C. C.; Lewis, J. S.; Mauguen, A.
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC)
    Meeting Abstract

    Campone, M.; Bardia, A.; Ulaner, G. A.; Chandarlapaty, S.; Gosselin, A.; Doroumian, S.; Pelekanou, V.; Celanovic, M.; Linden, H. M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Identification of HER2-positive metastases in patients with HER2-negative primary breast cancer by using HER2-targeted (89)Zr-pertuzumab PET/CT
    Journal Article

    Ulaner, G. A.; Carrasquillo, J. A.; Riedl, C. C.; Yeh, R.; Hatzoglou, V.; Ross, D. S.; Jhaveri, K.; Chandarlapaty, S.; Hyman, D. M.; Zeglis, B. M.; more...
    Radiology (2020)

    Fulltext@MSK | Save
  • Phase 1/2 dose-escalation and expansion study investigating SAR439859, a potent, oral, selective estrogen receptor degrader, +/- palbociclib in metastatic breast cancer
    Meeting Abstract

    Campone, M.; Bardia, A.; Ulaner, G. A.; Chandarlapaty, S.; Gosselin, A.; Doroumian, S.; Celanovic, M.; Linden, H. M.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Dose-escalation study of SAR439859, an oral selective estrogen receptor degrader, in postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer
    Meeting Abstract

    Campone, M.; Bardia, A.; Ulaner, G. A.; Chandarlapaty, S.; Gosselin, A.; Doroumian, S.; Ming, J.; Celanovic, M.; Linden, H. M.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Efficacy and determinants of response to HER kinase inhibition in HER2-mutant metastatic breast cancer
    Journal Article

    Smyth, L. M.; Piha-Paul, S. A.; Won, H. H.; Schram, A. M.; Saura, C.; Loi, S.; Lu, J.; Shapiro, G. I.; Juric, D.; Mayer, I. A.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Phase 1/2 dose-escalation and expansion study investigating SAR439859+/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2- metastatic breast cancer
    Meeting Abstract

    Bardia, A.; Linden, H. M.; Ulaner, G. A.; Chandarlapaty, S.; Gosselin, A.; Celanovic, M.; Campone, M.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2- metastatic breast cancer (mBC)
    Meeting Abstract

    Bardia, A.; Linden, H. M.; Ulaner, G. A.; Chandarlapaty, S.; Gosselin, A.; Doroumian, S.; Celanovic, M.; Campone, M.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save